89Bio Inc is a biotechnology company focused on developing innovative therapies for the treatment of liver and metabolic diseases
The company harnesses advanced biological research to create novel solutions aimed at addressing significant unmet medical needs in these areas. With a commitment to improving patient outcomes, 89Bio is dedicated to advancing its product pipeline and clinical programs, leveraging cutting-edge science and technology to deliver new treatment options for patients suffering from liver conditions and associated metabolic disorders.
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
After the conclusion of the US market's regular session on Friday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress 2024. Phase 2 tirzepatide trial shows promising results for MASH treatment. Further trials needed to confirm efficacy and safety.
Shares of Bitdeer Technologies Group (NASDAQBTDR) rose sharply during Monday’s session after the company reported preliminary fourth-quarter financial results, announced the successful testing of its SEAL01 Bitcoin mining chip and amid overall strength in the price of Bitcoin.
89Bio's journey in the clinical-stage biopharmaceutical space. RBC Capital Markets downgrades with insights on FGF21 drugs, pegozafermin, and 2024 uncertainties.
